Piper Sandler Increases Catalyst Pharma's Price Target Slightly After Q4 Earnings

  • Piper Sandler raised the price target marginally on Catalyst Pharmaceuticals Inc CPRX to $8.75 from $8.00, with an Overweight rating unchanged. 
  • Catalyst expects FY22 revenue of $195 million - $205 million, driven by transitioning ~125 patients previously on Ruzurgi onto Firdapse, analyst Joseph Catanzaro writes in a research note. 
  • Wall Street's estimate for sales is $198.45 million.
  • The Company's guidance reflects a continued recovery in macroeconomic and healthcare activity throughout 2022 related to the current COVID-19 environment.
  • The analyst notes that the growth in new patient enrollment in Q1 is on pace to exceed 2021, driving the analyst to push the Ruzurgi transition fully into Q1/Q2 and take the firm's Firdapse estimate up to $205 million.
  • The Company reported Q4 sales of $38 million, up 24% Y/Y, slightly ahead of the consensus of $38.19 million.
  • Catalyst Pharma's Q4 adjusted EPS reached $0.13, beating the consensus of $0.12.
  • Cash and investments were $191 million.
  • Price Action: CPRX shares are down 7.10% at $7.33 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!